Hologic makes more cuts in drive for profitability
This article was originally published in Clinica
Executive Summary
Becton Dickinson's shares fell from $36.70 to around $32.20 in the period after the company released its fourth-quarter and full-year results and forecast for 2002. The company says it is looking at options for increasing operating efficiency, including possibly "a smaller scale restructuring of manufacturing facilities in the BD medical systems segment". It is also considering divesting some smaller business units. Becton expects earnings-per-share growth of around 10% for 2002. "We continue to deliver revenue and earnings growth in line with the commitments we have made to our shareholders," said Edward Ludwig, CEO. The company's medical device unit had sales of $537 million in the quarter, up 7%. Total safety-engineered products' sales were $253 million in the year, a 55% increase. Becton's clinical laboratory solutions unit had sales of $295 million, a 10% increase.
You may also be interested in...
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.